Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement

Abstract

Brachytherapy xxx (xxxx) xxxLow dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement

Prostate brachytherapy utilization in the COVID-19 era: A cross-sectional study of radiation oncologists in the United States

“…However, the potential decrease in urinary toxicity with omission of BT in these patients must be weighed carefully against the improved bPFS offered by BT boost. ( 8 , 20 ) Similarly, concern for urinary toxicity may also influence the likelihood of offering BT monotherapy. However, the potential for increased urinary toxicity with BT alone must be balanced against decreased risk of secondary malignancy, erectile dysfunction, and gastrointestinal toxicity with respect to EBRT.…”

“…However, the potential for increased urinary toxicity with BT alone must be balanced against decreased risk of secondary malignancy, erectile dysfunction, and gastrointestinal toxicity with respect to EBRT. ( 20 )…”

“…However, the potential for increased urinary toxicity with BT alone must be balanced against decreased risk of secondary malignancy, erectile dysfunction, and gastrointestinal toxicity with respect to EBRT. (20) Limitations of this analysis result from the imperfections of survey research. For example, it is possible that the ROs who responded to our survey were not representative of the practicing population, as the response rate was 6%.…”

Sarcopenia and excess visceral fat accumulation negatively affect early urinary function after I‐125 low‐dose‐rate brachytherapy for localized prostate cancer

“…1 I-125 low-dose-rate brachytherapy (LDB) is a well-established treatment for clinically localized and low-, intermediate-, and high-risk localized PCA. 2 Treatment-related changes in quality of life (QOL) are important factors for determining the appropriate treatment. Lower urinary tract symptoms (LUTS) are major adverse events of LDB that can negatively impact QOL, especially in the early post-treatment period.…”

Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer

“…In Japan, approximately 94,000 men were newly diagnosed with prostate cancer in 2019, and the number of deaths from prostate cancer in the same year was about 12,500, with an increasing trend (2,3). For localized prostate cancer, guidelines list total prostatectomy, externalbeam radiation, and low-dose-rate brachytherapy (LDR-BT) as treatment options with good outcomes (4)(5)(6). The disease progression of local prostate cancer has already been clarified, and while active surveillance is an option, even with conservative therapy alone, the 15-year prostate cancerspecific survival rate is 88% and 65% for those with low-and intermediate-risk of treatment failure, respectively (7).…”